UBS Group’s IGC Pharma IGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $0 | Sell |
1
-8,096
| -100% | -$2.39K | ﹤0.01% | 10713 |
|
|
2026
Q1 | $2.13K | Sell |
8,097
-11,772
| -59% | -$3.27K | ﹤0.01% | 9351 |
|
|
2025
Q4 | $5.58K | Buy |
19,869
+16,824
| +553% | +$6K | ﹤0.01% | 8661 |
|
|
2025
Q3 | $1.27K | Sell |
3,045
-33,263
| -92% | -$12.7K | ﹤0.01% | 9390 |
|
|
2025
Q2 | $11.1K | Buy |
36,308
+36,307
| +3,630,700% | +$10.9K | ﹤0.01% | 8798 |
|
|
2025
Q1 | $0 | Sell |
1
-3,117
| -100% | -$983 | ﹤0.01% | 10459 |
|
|
2024
Q4 | $1.05K | Buy |
+3,118
| New | +$1.17K | ﹤0.01% | 9321 |
|
|
2024
Q1 | – | Sell |
-4,747
| Closed | -$1.33K | – | 9644 |
|
|
2023
Q4 | $1.33K | Buy |
4,747
+4,453
| +1,515% | +$1.38K | ﹤0.01% | 8338 |
|
|
2023
Q3 | $106 | Hold |
294
| – | – | ﹤0.01% | 8870 |
|
|
2023
Q2 | $92 | Hold |
294
| – | – | ﹤0.01% | 8522 |
|
|
2023
Q1 | $100 | Hold |
294
| – | – | ﹤0.01% | 9246 |
|
|
2022
Q4 | $94 | Hold |
294
| – | – | ﹤0.01% | 10410 |
|
|
2022
Q3 | $0 | Sell |
294
-15,885
| -98% | -$8.46K | ﹤0.01% | 10606 |
|
|
2022
Q2 | $8K | Buy |
16,179
+3,229
| +25% | +$2.04K | ﹤0.01% | 8310 |
|
|
2022
Q1 | $12K | Sell |
12,950
-2,497
| -16% | -$2.42K | ﹤0.01% | 8181 |
|
|
2021
Q4 | $15K | Sell |
15,447
-40,380
| -72% | -$54.2K | ﹤0.01% | 8246 |
|
|
2021
Q3 | $82K | Buy |
55,827
+47,399
| +562% | +$76.6K | ﹤0.01% | 5964 |
|
|
2021
Q2 | $14K | Buy |
8,428
+7,037
| +506% | +$10.7K | ﹤0.01% | 7706 |
|
|
2021
Q1 | $3K | Sell |
1,391
-28,774
| -95% | -$52.3K | ﹤0.01% | 8515 |
|
|
2020
Q4 | $47K | Buy |
30,165
+16,008
| +113% | +$23.7K | ﹤0.01% | 6244 |
|
|
2020
Q3 | $15K | Buy |
+14,157
| New | +$14.4K | ﹤0.01% | 6518 |
|
|
2020
Q2 | – | Sell |
-365
| Closed | – | – | 8133 |
|
|
2020
Q1 | $0 | Sell |
365
-12,464
| -97% | -$6.92K | ﹤0.01% | 8159 |
|
|
2019
Q4 | $8K | Buy |
12,829
+9,916
| +340% | +$8.11K | ﹤0.01% | 7388 |
|
|
2019
Q3 | $3K | Buy |
+2,913
| New | +$3.51K | ﹤0.01% | 7634 |
|
|
2019
Q2 | – | Sell |
-5,727
| Closed | -$12K | – | 7992 |
|
|
2019
Q1 | $12K | Buy |
+5,727
| New | +$13K | ﹤0.01% | 6685 |
|
|
2018
Q4 | – | Sell |
-2,991
| Closed | -$19K | – | 8149 |
|
|
2018
Q3 | $19K | Sell |
2,991
-585
| -16% | -$608 | ﹤0.01% | 6822 |
|
|
2018
Q2 | $2K | Buy |
+3,576
| New | +$2.06K | ﹤0.01% | 7728 |
|
|
2017
Q4 | – | Sell |
-29,838
| Closed | -$11K | – | 7957 |
|
|
2017
Q3 | $11K | Sell |
29,838
-41,884
| -58% | -$15.5K | ﹤0.01% | 6827 |
|
|
2017
Q2 | $29K | Buy |
71,722
+67,837
| +1,746% | +$30.3K | ﹤0.01% | 6033 |
|
|
2017
Q1 | $2K | Sell |
3,885
-30,416
| -89% | -$9.62K | ﹤0.01% | 7285 |
|
|
2016
Q4 | $10K | Buy |
34,301
+28,647
| +507% | +$9.94K | ﹤0.01% | 6920 |
|
|
2016
Q3 | $3K | Buy |
+5,654
| New | +$2.74K | ﹤0.01% | 7282 |
|
|
2016
Q2 | – | Sell |
-13,128
| Closed | -$7K | – | 7834 |
|
|
2016
Q1 | $7K | Buy |
13,128
+3,023
| +30% | +$915 | ﹤0.01% | 6853 |
|
|
2015
Q4 | $2K | Buy |
10,105
+5,968
| +144% | +$1.19K | ﹤0.01% | 8009 |
|
|
2015
Q3 | $1K | Sell |
4,137
-7,439
| -64% | -$2.02K | ﹤0.01% | 8220 |
|
|
2015
Q2 | $5K | Buy |
+11,576
| New | +$5.1K | ﹤0.01% | 7868 |
|
|
2015
Q1 | – | Sell |
-7,048
| Closed | -$5K | – | 9035 |
|
|
2014
Q4 | $5K | Buy |
+7,048
| New | +$5.1K | ﹤0.01% | 8970 |
|
Other funds holding IGC
AI
LC
UBS Group's IGC Position: Q2 2026 in Review
UBS Group reduced its IGC Pharma (IGC) stake by 100% in Q2 2026, selling an estimated $2.39K and leaving 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #10713.
UBS Group first reported a position in IGC in Q4 2014 and has held it in 37 quarters since. The position peaked at $82K in Q3 2021. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.
- UBS Group held 1 share of IGC Pharma worth $0 as of Q2 2026.
- UBS Group sold 8,096 IGC Pharma shares in Q2 2026, an estimated $2.39K.
- IGC Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10713 holding.
- UBS Group first reported a position in IGC Pharma in Q4 2014 and has held it in 37 quarters since.
- UBS Group's IGC Pharma position peaked at $82K in Q3 2021.
- 36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.